<table style="border:1px solid #adadad; background-color: #F3F1EC; color: #666666; padding:8px; -webkit-border-radius:4px; border-radius:4px; -moz-border-radius:4px; line-height:16px; margin-bottom:6px;" width="100%">
<tbody>
<tr>
<td><span style="font-family:Helvetica, sans-serif; font-size:20px;font-weight:bold;">Health Tech | Fierce Healthcare</span></td>
</tr>
<tr>
<td> </td>
</tr>
</tbody>
</table>
<table style="font:13px Helvetica, sans-serif; border-radius:4px; -moz-border-radius:4px; -webkit-border-radius:4px; background-color:#fff; padding:8px; margin-bottom:6px; border:1px solid #adadad;" width="100%">
<tbody>
<tr>
<td><a href="https://www.fiercehealthcare.com/digital-health/covera-health-medmo-combine-create-first-complete-diagnostic-imaging-platform" style="font-family:Helvetica, sans-serif; letter-spacing:-1px;margin:0;padding:0 0 2px;font-weight: bold;font-size: 19px;line-height: 20px;color:#222;">Covera Health, Medmo create coordinated imaging platform</a>
<div style="font-family:Helvetica, sans-serif; text-align:left;color:#999;font-size:11px;font-weight:bold;line-height:15px;">Apr 22nd 2026, 13:45</div>
<div style="font-family:Helvetica, sans-serif; color:#494949;text-align:justify;font-size:13px;">
<p><div class="col content" morss_own_score="5.329032258064516" morss_score="39.63020566093283">
<p>Digital health companies Covera Health and Medmo <a href="https://www.prnewswire.com/news-releases/covera-health-and-medmo-combine-to-deliver-the-first-platform-that-manages-the-complete-radiology-journey-from-imaging-order-to-accurate-diagnosis-302748407.html?tc=eml_cleartime">combined</a> into a single organization on Tuesday to form an end-to-end platform that manages diagnostic imaging.</p>
<p>The platform will reach nearly six million Americans across all 50 states, the companies say, ranging from Fortune 10 and 100 employers, three of the five biggest national health plans and thousands of value-based primary care physicians. </p>
<p>Covera Health uses its artificial intelligence-driven platform to measure diagnostic accuracy at more than 1,100 imaging locations across the U.S. and analyzes completed imaging to flag clinically significant information to route back to clinical decision makers. It has analyzed 21 million patient journeys, generating more than 679,000 insights, its <a href="https://www.coverahealth.com/ourwork.html">website</a> says. </p>
<p>Meanwhile, Medmo is a care coordination platform for diagnostic imaging, partnering with value-based care organizations, primary care groups, ACOs and health plans. Its focus is on ensuring patients reach the correct imaging centers, complete tests and receive timely follow-up care. The company says it has aided in more than one million cases, showing a 35% decrease in spending and a 30% increase in study completion rates. </p>
<p>Covera Health led Medmo’s <a href="https://www.globenewswire.com/news-release/2025/10/14/3166303/0/en/Medmo-Raises-15-Million-Series-A-Funding-Round.html">$15 million series A funding round</a>, announced in October.</p>
<p>Covera Health CEO Ron Vianu said in a statement that the location a patient receives an imaging test “is not a neutral decision,” adding it can “produce a meaningfully different diagnosis” depending on the site and clinicians. </p>
<p>“That variation was always there,” Vianu said. “Covera built the infrastructure to measure it for the first time and proved that routing patients to the right facility produces meaningfully better outcomes. What we could not do alone was ensure patients reliably reached the right place to begin with, and that the result connected back to the physician and care team who needed to act on it. Medmo solved that. It is the first platform in radiology that closes the loop from the moment a referral is written to the moment a patient is on the right care path.” </p>
<p>Vianu will remain the CEO of Covera Health. Medmo CEO Lucas Takahashi will continue serving as the company’s CEO, but will also take on the role of president for the combined organization. </p>
<p>Takahashi said in a statement that healthcare providers can “lose visibility” when patients leave with imaging orders. </p>
<p>“Medmo closes that gap, ensuring patients reach the right facility, complete their study, and that results get back to the physician who needs to act on them,” Takahashi said. “Joining with Covera means that every step of that journey now carries clinical intelligence. Together, we've built something new for radiology: a platform that delivers quality and coordination as one.” </p>
</div></p>
</div>
<div style="font-family:Helvetica, sans-serif; font-size:13px; text-align: center; color: #666666; padding:4px; margin-bottom:2px;"></div>
</td>
</tr>
</tbody>
</table>
<table style="font:13px Helvetica, sans-serif; border-radius:4px; -moz-border-radius:4px; -webkit-border-radius:4px; background-color:#fff; padding:8px; margin-bottom:6px; border:1px solid #adadad;" width="100%">
<tbody>
<tr>
<td><a href="https://www.fiercehealthcare.com/ai-and-machine-learning/amperos-health-secures-16m-series-funding-announces-industrys-new-first-ai" style="font-family:Helvetica, sans-serif; letter-spacing:-1px;margin:0;padding:0 0 2px;font-weight: bold;font-size: 19px;line-height: 20px;color:#222;">Amperos Health nabs $16M for billing automation tools</a>
<div style="font-family:Helvetica, sans-serif; text-align:left;color:#999;font-size:11px;font-weight:bold;line-height:15px;">Apr 22nd 2026, 13:45</div>
<div style="font-family:Helvetica, sans-serif; color:#494949;text-align:justify;font-size:13px;">
<p><div class="col content" morss_own_score="5.3478260869565215" morss_score="78.79202835373943">
<p>Artificial intelligence startup Amperos Health raised $16 million in series A funding as it continues to automate revenue cycle management using AI. </p>
<p>Bessemer Venture Partners led the series A round, with participation from Uncork Capital and Neo. Sofia Guerra, partner at Bessemer Venture Partners, told Fierce Healthcare the company knew AI was “going to be a big driver of automating” the RCM process, adding that Amperos stood out for its quality, technical approach and results.</p>
<p>“When you get on the phone with a customer and they have raving reviews, that's where you really pay attention,” Guerra said. “And Amperos had a lot of that.” </p>
<p>The company <a href="https://www.prnewswire.com/news-releases/amperos-health-launches-amanda-the-worlds-first-ai-biller-for-healthcare-denials-and-collections-302472761.html">raised $4.2 million</a> in a seed funding round from Uncork Capital, Neo and Nebular, with strategic angel investors from OpenAI, Twilio and Stripe. It has raised $21 million to date.</p>
<p>Amperos Health CEO and co-founder Michal Miernowski told Fierce Healthcare the company plans to use the newly announced funding to scale the existing organization. </p>
<p>“We've been able to help our customers recover about $700 million of outstanding claims per year, but if you look at how much revenue is denied in the industry, it's about $262 billion per year,” Miernowski said. “So we're only really scratching the surface.”</p>
<p>Initial claims denials reached <a href="https://www.businesswire.com/news/home/20250521892947/en/Rate-of-initial-denials-of-medical-insurance-claims-continued-to-rise-in-2024-Kodiak-Solutions-proprietary-data-show">nearly 12%</a> in 2024, and increased denials and subsequent revenue losses led to providers spending more than $26 billion annually on recovering denied claims, the company said in the announcement.</p>
<p>Miernowski said the funding will also work to scale Amperos’ platform. “We'll be launching other modules later this year that start going across those different RCM teams, including things like prior auth [and] insurance verification,” Miernowski said. </p>
<p>Alongside the funding announcement, Amperos announced the launch of what the company calls the industry’s first AI-native denial management and revenue recovery end-to-end solution for providers. </p>
<p>Miernowski said the way the tool works is “very similar, almost to a human being working the claim,” adding the solution sits within existing systems and has a range of functions, including navigating insurance websites and filling out appeals.</p>
<p>“We do have a team of human experts that can jump in, and then what we deliver to our customers is those end-to-end worked claims,” Miernowski said.</p>
<p>The platform uses large language models (LLMs) to complete entire RCM workflows and maximize reimbursement at the lowest cost to collect. Miernowski said feedback on the tool has been positive across entire organizations, citing a large provider with a national footprint that was “severely understaffed.”</p>
<p>“We’re able to help them collect over $60 million of collections within just eight weeks,” Miernowski said. </p>
<p>Providers of all sizes are feeling the pressure from payers, Guerra said, though small and mid-size providers often find themselves “in the never-ending loop” of work. “Amperos is really taking a lot of that work and pain, and doing that with technology,” she said.</p>
<p>“It's not just a productivity boost that it gives those teams,” Guerra said. “But also, the recovery rate and win rate, and being able to deliver a service end-to-end that's a lot cheaper than alternatives.”</p>
<p>The company says it has served more than 3,000 clinical locations across the U.S. to date, driving nearly $700,000 million in recovered revenue per year across more than 500,000 claims.</p>
<p>Blue Ash, Ohio-based DOCS Dermatology is one of the providers partnering with Amperos. DOCS Vice President of RCM Valerie DeCaro told Fierce Healthcare the group was looking for “solutions to help augment our workflow” amid rapid growth, maintain “discipline around our cost to collect,” policy changes and shifting administrative burden. </p>
<p>“[We] just realized that if we want to continue to scale in the way that we know we will, we needed some type of automation AI to help us get there at the same time,” DeCaro said. </p>
<p>DeCaro said the organization has been “focused on leveraging” Amperos’ auto-claim statusing tool and has seen “strong success.”</p>
<p>“It's helped us to accelerate our staff production, helped us gain greater visibility into a claim status,” DeCaro said. “And ultimately just drive more efficient follow-up and collection activity to help us get to our KPI.” </p>
</div></p>
</div>
<div style="font-family:Helvetica, sans-serif; font-size:13px; text-align: center; color: #666666; padding:4px; margin-bottom:2px;"></div>
</td>
</tr>
</tbody>
</table>
<table style="font:13px Helvetica, sans-serif; border-radius:4px; -moz-border-radius:4px; -webkit-border-radius:4px; background-color:#fff; padding:8px; margin-bottom:6px; border:1px solid #adadad;" width="100%">
<tbody>
<tr>
<td><a href="https://www.fiercehealthcare.com/health-tech/oak-hcft-backs-courier-healths-50m-series-b-build-out-ai-biopharma-patient-experience" style="font-family:Helvetica, sans-serif; letter-spacing:-1px;margin:0;padding:0 0 2px;font-weight: bold;font-size: 19px;line-height: 20px;color:#222;">Courier Health pockets $50M for AI-powered patient experience</a>
<div style="font-family:Helvetica, sans-serif; text-align:left;color:#999;font-size:11px;font-weight:bold;line-height:15px;">Apr 22nd 2026, 13:45</div>
<div style="font-family:Helvetica, sans-serif; color:#494949;text-align:justify;font-size:13px;">
<p><div class="col content" morss_own_score="5.890210430009149" morss_score="75.00675454765621">
<p>Prescribing medications to patients is only one step to improve their health, as making sure that patients start therapies and stay on them is a critical part of the process.</p>
<p>From prescription to long-term adherence, there continue to be major gaps in the patient experience. Many life sciences companies find that efforts to engage and support patients once they are prescribed their medicines still fall short due to siloed data, disparate systems and poor coordination. </p>
<p>Courier Health launched in 2022 with an artificial intelligence-powered platform purpose-built for biopharma that manages the end-to-end patient journey from education to patient enrollment, benefits and prior authorization, through therapy initiation and adherence. Courier Health's AI agents can automate tasks like intake, benefits checks and information requests, according to the company.</p>
<p>Courier Health raised $50 million in series B funding led by Oak HC/FT, with participation from existing investors including Norwest Venture Partners and Work-Bench. Norwest Venture Partners and Work-Bench also backed the company's $16.5 million series A funding round in July 2024 as Courier Health built out its customer relationship management (CRM) platform for life sciences companies.</p>
<p>The startup aims to "re-write the patient experience in healthcare," starting with simplifying and coordinating complex patient journeys for those who depend on innovative medicines, Danny Sigurdson, founder and CEO of Courier Health, said.</p>
<p>"As focus has been to help engage and support patients on their journey when they have a chronic condition or rare disease, and the medicine is a really important part of that journey," he told Fierce Healthcare in an interview.</p>
<p>The fresh funding will fuel Courier Health's investment in product innovation, including scaling its agentic AI capabilities, and building out its team as it hires across product, engineering, client solutions and sales, according to executives.</p>
<p>Nearly 60% of biopharma companies consider their data fragmented or inactionable, and less than 10% have sufficient data maturity to leverage AI in a meaningful way, according to a recent <a href="https://www.courierhealth.com/resources/2026-patient-centricity-report">report</a>.</p>
<p>Courier Health built technology to solve these pain points by connecting data and systems related to the patient experience, applying intelligence to surface insights and proactively identify at-risk patients, executives said. </p>
<h3>Related</h3>
<a href="https://www.fiercehealthcare.com/payers/playbook-boost-medication-adherence"><span>A playbook to boost medication adherence</span>
</a>
<p>Despite the billions spent in drug R&D and getting a medication to market, there continue to be challenges with getting approved medications into patients' hands with many biopharma companies seeing low activation and retention rates.</p>
<p>More than half of prescriptions for newly launched specialty drugs never reach patients, according to <a href="https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/understanding-the-use-of-medicines-in-the-us-2025">IQVIA data</a>. IQVIA’s 2024 pharmacy claims analysis followed prescriptions for novel active substances launched in 2022-2023. For all claims, 52% were rejected by the original payor, 13% eventually approved by a different payor, and 39% rejected by all payors. That means that 61% of original claims were ultimately approved and filled—but 17% were later abandoned, meaning that only 44% actually reached patients. </p>
<p>"There is a lot of money that goes into driving awareness to physicians, to patients, to communities, but there are pretty abysmal rates at enabling patients and their physicians, frankly, to be successful and achieve the health outcomes that we all expected," Sigurdson said. "For every 10 patients prescribed specialty therapy, three don't even start, and another three or four discontinue in the first few months."</p>
<p>"When we talk about helping deliver a better patient experience, it's about taking all of that complexity out of that final mile of the process. It's about bringing together the data that is out there and exists that's coming from the providers, the payers, the prior authorization systems, the pharmacies, financial assistance, foundations, communities, sometimes educators, all the various offerings and bringing that together in one place to orchestrate a more seamless patient experience that is better for the patients, better for providers, and people are actually able to access and have a chance of being successful in their innovative medicines," Sigurdson said. </p>
<p>Courier Health designed a platform with deep data integrations, intelligent workflows driven by context-rich AI, intuitive user interfaces designed specifically for market access and patient services teams, and AI agents that can execute key tasks for reliable automation and scale. The aim is to give biopharma teams better visibility, control and data intelligence to ensure high-quality interactions with providers, pharmacies, as well as patients and their families, executives said.</p>
<p>"From an agentic perspective, we really think about what are the opportunities to support the human users, patient services teams and field reimbursement teams. There are also opportunities where there are pretty clear outcomes that we can execute against to help supplement those human users and actually do the work agentically. On processing patient intakes, for example, AI agents can be powerful because you can explain that clearly defined outcome. You can put boundaries around what we're asking the AI agent to do. We do a lot of work to ensure it's secure and compliant, but it allows it to work autonomously and very intelligently in a way that gives the human users time back to focus on the higher-level tasks that would require empathy and creative thinking and human-to-human interactions," Sigurdson said.</p>
<p>Courier Health plans to continue investing in AI capabilities to integrate and connect data, orchestrate workflows and execute patient engagement activities, "whether that's AI supplementing our human users or agentic AI fully executing certain tasks that have clear outcomes," he noted.</p>
<p>In 2025, Courier Health increased the number of customers and therapies supported on its platform by over 400% and more than doubled its headcount to meet market demand. The company claims that its clients see a 15% to 20% increase in patient starts and a 10% to 12% increase in six-month persistency.</p>
<p>“Healthcare, especially life sciences, has long lacked a dedicated, purpose-built platform to manage patients,” said Billy Deitch, partner at Oak HC/FT, in a statement. “True patient-centricity is often promised but rarely delivered, and Courier Health changes that narrative. They provide essential infrastructure and an incredibly thoughtful AI strategy that biopharma is excited to adopt at a rapid pace. Oak is proud to partner with Danny and his team as they redefine the standard for the patient experience.”</p>
</div></p>
</div>
<div style="font-family:Helvetica, sans-serif; font-size:13px; text-align: center; color: #666666; padding:4px; margin-bottom:2px;"></div>
</td>
</tr>
</tbody>
</table>
<p><strong>Forwarded by:<br />
Michael Reeder LCPC<br />
Baltimore, MD</strong></p>
<p><strong>This information is taken from free public RSS feeds published by each organization for the purpose of public distribution. Readers are linked back to the article content on each organization's website. This email is an unaffiliated unofficial redistribution of this freely provided content from the publishers. </strong></p>
<p> </p>
<p><s><small><a href="#" style="color:#ffffff;"><a href='https://blogtrottr.com/unsubscribe/55wMX0?signature=d3c0935c0cdbd702ef36555e19dabf249df69613966bbb1ace8ed255419b1ff3'>unsubscribe from this feed</a></a></small></s></p>